New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model

[1]  J. Mascola,et al.  Chimpanzee Adenovirus Vector Ebola Vaccine , 2017, The New England journal of medicine.

[2]  A. Nicosia,et al.  Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults , 2015, Science Translational Medicine.

[3]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[4]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[5]  R. Cortese,et al.  Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals , 2014, The Journal of infectious diseases.

[6]  Bjoern Peters,et al.  Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes , 2014, PloS one.

[7]  Mario Roederer,et al.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge , 2014, Nature Medicine.

[8]  G. van Gemert,et al.  Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites , 2014, The Journal of infectious diseases.

[9]  A. Folgori,et al.  Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.

[10]  D. Weiner,et al.  Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants , 2013, Front. Immunol..

[11]  D. Ho,et al.  A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+ T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates , 2013, PloS one.

[12]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[13]  D. Brough,et al.  Adenoviruses isolated from wild gorillas are closely related to human species C viruses. , 2013, Virology.

[14]  Andrea J. Radtke,et al.  In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages , 2013, Proceedings of the National Academy of Sciences.

[15]  Kevin Marsh,et al.  Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. , 2013, The New England journal of medicine.

[16]  R. Cortese,et al.  Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults , 2013, PloS one.

[17]  Kylie M. Quinn,et al.  Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization , 2013, The Journal of Immunology.

[18]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[19]  G. Nabel.  Designing tomorrow's vaccines. , 2013, The New England journal of medicine.

[20]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[21]  Daniel E. Zak,et al.  Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity , 2012, Proceedings of the National Academy of Sciences.

[22]  S. Dalai,et al.  Memory CD8 T Cells Specific for Plasmodia Liver-Stage Antigens Maintain Protracted Protection Against Malaria , 2012, Front. Immun..

[23]  D. Doolan,et al.  Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses , 2012, PloS one.

[24]  R. Cortese,et al.  Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors , 2012, PloS one.

[25]  W. Weiss,et al.  Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites , 2012, PloS one.

[26]  A. Folgori,et al.  Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species , 2012, Science Translational Medicine.

[27]  A. Folgori,et al.  Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.

[28]  D. Carucci,et al.  Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component , 2011, PloS one.

[29]  R. Sinden,et al.  A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine , 2011, Vaccine.

[30]  Mario Roederer,et al.  CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates , 2011, Nature Medicine.

[31]  K. Mansfield,et al.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.

[32]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[33]  J. Sacci,et al.  Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates , 2011, Malaria Journal.

[34]  Joshua C. Johnson,et al.  Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge , 2011, Journal of Virology.

[35]  M. Tsuji.  A retrospective evaluation of the role of T cells in the development of malaria vaccine. , 2010, Experimental parasitology.

[36]  A. Folgori,et al.  Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.

[37]  J. Aguiar,et al.  Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies , 2009, PloS one.

[38]  J. Sallenave,et al.  Intranasal Mucosal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances the Protection of BCG-Primed Guinea Pigs against Pulmonary Tuberculosis , 2009, PloS one.

[39]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[40]  F. Zavala,et al.  Protective CD8+ T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response , 2008, Immunological reviews.

[41]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  S. Hoffman,et al.  Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+ T cell mediated protective immunity against malaria. , 2007, Molecular immunology.

[43]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[44]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[45]  S. Ellenberg,et al.  Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa , 2006, Emerging infectious diseases.

[46]  K. Marsh,et al.  Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. , 2006, Vaccine.

[47]  D. Webster,et al.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Bojang,et al.  A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults , 2004, PLoS medicine.

[49]  H. Whittle,et al.  Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States , 2004, Clinical Diagnostic Laboratory Immunology.

[50]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[51]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[52]  S. Hoffman,et al.  Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations , 2002, Infection and Immunity.

[53]  A. Hill,et al.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. , 2002, Vaccine.

[54]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  James M. Wilson,et al.  Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. , 1997, Journal of immunology.

[56]  D. Brough,et al.  A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4 , 1996, Journal of virology.

[57]  S. Hoffman,et al.  Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. , 1990, Immunology letters.

[58]  J. Berzofsky,et al.  Genetic control of immunity to Plasmodium yoelii sporozoites. , 1989, Journal of immunology.

[59]  L. Schofield.  T cell immunity to malaria sporozoites. , 1989, Experimental parasitology.

[60]  L. Yuan,et al.  Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens , 1987, Infection and immunity.

[61]  D. Brough,et al.  Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  J. Stockman.  First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[63]  M. Good,et al.  CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. , 1988, Proceedings of the National Academy of Sciences of the United States of America.